TP53 and osteosarcoma: The NCI-GEO study included 1,499 osteosarcoma cases that underwent germline WES and/or TP53 targeted sequencing, of which 45 osteosarcoma cases were determined to have 35 unique germline TP53 variants that met inclusion criteria (Supplementary Table 1).